Flummoxing views on aducanumab
The health care analysts at J.P. Morgan conducted a poll of Alzheimer’s doctors to gauge their feelings about Biogen’s controversial Alzheimer’s drug candidate aducanumab.
"Based on the data derived from Biogen’s twin, Phase 3 studies, should the FDA approve aducanumab?” asked J.P. Morgan. Two-thirds of the responding docs said no, do not approve this Alzheimer’s drug.
J.P. Morgan then asked, if the FDA approves aducanumab anyway, will you prescribe it to Alzheimer’s patients? The answer: Yes! Polled doctors said that, two years after approval, they'd prescribe aducanumab to about 40% of their patients with mild cognitive impairment or mild Alzheimer’s.
What do these contradictory responses mean? The need for an effective Alzheimer’s medicine is enormous; any treatment that might offer a sliver of efficacy, no matter how small, will likely be approved and widely used.
"Based on the data derived from Biogen’s twin, Phase 3 studies, should the FDA approve aducanumab?” asked J.P. Morgan. Two-thirds of the responding docs said no, do not approve this Alzheimer’s drug.
J.P. Morgan then asked, if the FDA approves aducanumab anyway, will you prescribe it to Alzheimer’s patients? The answer: Yes! Polled doctors said that, two years after approval, they'd prescribe aducanumab to about 40% of their patients with mild cognitive impairment or mild Alzheimer’s.
What do these contradictory responses mean? The need for an effective Alzheimer’s medicine is enormous; any treatment that might offer a sliver of efficacy, no matter how small, will likely be approved and widely used.
.png)
No hay comentarios:
Publicar un comentario